cbp 501
Peptideexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2006 (NCT00551512)
Timeline
Indications
Mechanism of action
MAPKAPK2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- cbp501
- cbp501
- cbp501
- cbp 501
- cbp-501
- cdc25c phosphatase (211-221)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04953962 | Phase 2 | Nov 30, 2021 | CanBas Co. Ltd. |
| NCT03113188 | Phase 1 | May 1, 2017 | CanBas Co. Ltd., Harvard University |
| NCT00942825 | Phase 2 | Apr 1, 2009 | CanBas Co. Ltd. |
| NCT00700336 | Phase 1/Phase 2 (Phase 2) | May 1, 2008 | CanBas Co. Ltd. |
| NCT00551512 | Phase 1 | Nov 1, 2006 | AAIPharma, CanBas Co. Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CanBas Co. Ltd. | For profit | 5 | 5 | 2 | 2006 |
| AAIPharma | For profit | 1 | 0 | 1 | 2006 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1